AJTMH ASTMH MEMBERSHIP INFORMATION: astmh@astmh.org
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 59(3), 1998, pp. 426-430
Copyright © 1998 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Atta, A.
Right arrow Articles by Carvalho, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Atta, A.
Right arrow Articles by Carvalho, E.
Related Collections
Right arrow Leishmaniasis
American Journal of Tropical Medicine and Hygiene, Vol 59, Issue 3, 426-430
Copyright © 1998 by American Society of Tropical Medicine and Hygiene

Research Articles


Anti-leishmanial IgE antibodies: a marker of active disease in visceral leishmaniasis

AM Atta, D'Oliveira, J Correa, ML Atta, RP Almeida, and EM Carvalho

Visceral leishmaniasis (VL) is characterized by a depression of the T helper cell type 1 immune response. Although mRNA expression for interleukin-4 (IL-4) is observed, evidence of the role of this cytokine in the pathogenesis of VL has been lacking. Since IL-4 is involved in IgE synthesis, we measured the total IgE and Leishmania antigen-specific IgE antibody levels in sera from patients with VL. Specific IgE antibodies detected by an ELISA technique after absorbing the sera with purified sheep IgG anti-human IgG were found in all 23 patients with VL and were not detected in subjects with subclinical Leishmania chagasi infection (n = 10), Chagas' disease (n = 10), atopic patients (n = 10), and healthy controls (n = 10). Levels of Leishmania-specific IgE (optical density values) before and after treatment were 0.100 +/- 0.03 (mean +/- SD) and 0.028 +/- 0.002, respectively (P < 0.05). These results indicate that a specific IgE response is useful in the diagnosis of active disease and to evaluate response to treatment.


This article has been cited by other articles:


Home page
 Am J Trop Med HygHome page
H. TAKAGI, M. Z. ISLAM, M. ITOH, A. U. ISLAM, A. R. M. SAIFUDDIN EKRAM, S. M. HUSSAIN, Y. HASHIGUCHI, and E. KIMURA
PRODUCTION OF RECOMBINANT KINESIN-RELATED PROTEIN OF LEISHMANIA DONOVANI AND ITS APPLICATION IN THE SERODIAGNOSIS OF VISCERAL LEISHMANIASIS
Am J Trop Med Hyg, May 1, 2007; 76(5): 902 - 905.
[Abstract] [Full Text] [PDF]

Home page
 J Med MicrobiolHome page
H. Ozbilge, N. Aksoy, M. S. Gurel, and S. Yazar
IgG and IgG subclass antibodies in patients with active cutaneous leishmaniasis.
J. Med. Microbiol., October 1, 2006; 55(Pt 10): 1329 - 1331.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
S. Saha, T. Mazumdar, K. Anam, R. Ravindran, B. Bairagi, B. Saha, R. Goswami, N. Pramanik, S. K. Guha, S. Kar, et al.
Leishmania Promastigote Membrane Antigen-Based Enzyme-Linked Immunosorbent Assay and Immunoblotting for Differential Diagnosis of Indian Post-Kala-Azar Dermal Leishmaniasis
J. Clin. Microbiol., March 1, 2005; 43(3): 1269 - 1277.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
R. Ravindran, K. Anam, B. C. Bairagi, B. Saha, N. Pramanik, S. K. Guha, R. P. Goswami, D. Banerjee, and N. Ali
Characterization of Immunoglobulin G and Its Subclass Response to Indian Kala-Azar Infection before and after Chemotherapy
Infect. Immun., February 1, 2004; 72(2): 863 - 870.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
M. L. B. Sousa-Atta, G. S. Salame, A. D'Oliveira Jr, R. P. Almeida, A. M. Atta, and E. M. Carvalho
Immunoglobulin E Antileishmanial Antibody Response in Cutaneous Leishmaniasis
Clin. Vaccine Immunol., January 1, 2002; 9(1): 101 - 104.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
H. W. Murray
Clinical and Experimental Advances in Treatment of Visceral Leishmaniasis
Antimicrob. Agents Chemother., August 1, 2001; 45(8): 2185 - 2197.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Society of Tropical Medicine and Hygiene.